Published • loading... • Updated
Axsome: Q3 Earnings Snapshot – WTOP News
Philips booked a €288 million provision as its Respironics unit works to resolve U.S. investigations tied to the sleep device recall.
- Axsome Therapeutics, a biopharmaceutical company, reported third-quarter 2026 revenue of $260 million, a 52% year-over-year increase, while narrowing its net loss to $12.9 million.
- Advancing its 10-program neuroscience pipeline, Axsome initiated the SUMMIT Phase III trial of AXS-05 for smoking cessation and reached targeted enrollment in its binge eating disorder study.
- AUVELITY prescriptions reached 302,000 in the third quarter, a 40% year-over-year increase; the company also activated 8,200 new unique prescribers during the same period.
- Funding operations through cash-flow positivity remains a priority, with Axsome maintaining a $313.9 million cash balance to support its path toward that goal.
- By May 1, 2027, the Food and Drug Administration is expected to act on the new drug application for AXS-12, a critical milestone for expanding the company's sleep franchise.
Insights by Ground AI
92 Articles
92 Articles
Coverage Details
Total News Sources92
Leaning Left18Leaning Right10Center27Last UpdatedBias Distribution49% Center
Bias Distribution
- 49% of the sources are Center
49% Center
L 33%
C 49%
R 18%
Factuality
To view factuality data please Upgrade to Premium
